Login
$SION
$3.12 +$0.00 (0.0%) After hours

$SION 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027

14 Sep 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride

10 Aug 2026 8-K: Other Events

SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care

06 Aug 2026 8-K: Results of Operations and Financial Condition

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 45,142,330 shares of the Company's common stock outstanding as of the record date of April 21,...

12 May 2026 8-K: Results of Operations and Financial Condition

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026

02 Mar 2026 8-K: Results of Operations and Financial Condition

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026

05 Nov 2025 8-K: Results of Operations and Financial Condition

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis

11 Aug 2025 8-K: Results of Operations and Financial Condition

Announced Positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 12, 2025, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 44,124,394 shares of the Company's common stock outstanding as of the record date of April 15,...

04 Jun 2025 8-K: Regulation FD Disclosure

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that

12 May 2025 8-K: Results of Operations and Financial Condition

Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated

20 Mar 2025 8-K: Results of Operations and Financial Condition

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025

10 Feb 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support